- Home
- RLAY vs MIST Comparison
RLAY vs MIST Comparison
Compare RLAY & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | MIST |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 176.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLAY | MIST |
|---|---|---|
| Price | $7.98 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $16.00 | $8.50 |
| AVG Volume (30 Days) | 2.3M | ★ 9.9M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $20.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $0.63 |
| 52 Week High | $9.04 | $3.06 |
Technical Indicators
Market Signals| Indicator | RLAY | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 41.50 |
| Support Level | $8.25 | $1.94 |
| Resistance Level | $8.58 | $2.10 |
| Average True Range (ATR) | 0.44 | 0.20 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 22.83 | 10.71 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).